Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.

Saved in:
Bibliographic Details
Title: Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.
Authors: Bendell JC; Sarah Cannon Research Institute, Nashville, TN, USA. jbendell@tnonc.com, Ervin TJ, Gallinson D, Singh J, Wallace JA, Saleh MN, Vallone M, Phan SC, Hack SP
Source: Clinical colorectal cancer [Clin Colorectal Cancer] 2013 Sep; Vol. 12 (3), pp. 218-22. Date of Electronic Publication: 2013 Jun 27.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1938-0674
DOI:10.1016/j.clcc.2013.04.001